Axsome Therapeutics
AXSM
11 hedge funds and large institutions have $47.7M invested in Axsome Therapeutics in 2015 Q4 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
27.24% more ownership
Funds ownership: 0% → 27.24% (+27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.3M |
| 2 |
JP Morgan Chase
New York
|
+$13.7M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$3M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.94M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$1.03M |
Top Sellers
AXSM Hedge Fund Activity: Q4 2015 in Review
11 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2015, worth a combined $47.7M.
Buyers outnumbered sellers: 11 funds opened new AXSM positions and 0 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $25.3M.
- 11 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2015, up from 0 in Q3 2015.
- Funds reported $47.7M of Axsome Therapeutics stock for Q4 2015.
- 11 funds opened new Axsome Therapeutics positions in Q4 2015 and 0 closed out, a net change of +11 holders.
- The largest Axsome Therapeutics buyer in Q4 2015 was Fidelity Investments, an estimated $25.3M added.
Based on aggregated 13F filings for Q4 2015.